News | December 05, 2025
Lupin inks US licensing deal with Valorum for biosimilar Armlupeg
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
Subscribe To Our Newsletter & Stay Updated
